AZD 5312

Drug Profile

AZD 5312

Alternative Names: AZD5312; IONIS AR 2.5Rx; ISIS ARRX; ISIS AZ1Rx; ISIS-560131; ISIS-ARRx

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer AstraZeneca; Ionis Pharmaceuticals
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Discontinued Solid tumours

Most Recent Events

  • 15 Nov 2016 Adverse events, pharmacokinetic and pharmacodynamic data from a phase I/II trial in advanced solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 16 Jun 2016 Phase-II clinical trials in Prostate cancer (Late-stage disease) in United Kingdom and USA (IV) (Ionis Pharmaceuticals pipeline, June 2016)
  • 02 May 2016 Discontinued - Phase-I/II for Solid tumours (Late-stage disease) in United Kingdom (IV) (AstraZeneca pipeline, May 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top